Larry G. Edwards - 31 Mar 2022 Form 4 Insider Report for LA JOLLA PHARMACEUTICAL CO

Role: Chief Executive Officer
Signature: /s/ Larry Edwards
Issuer symbol: N/A
Transactions as of: 31 Mar 2022
Net transactions value: +$1,212
Form type: 4
Filing time: 04 Apr 2022, 17:39:56 UTC
Previous filing: 17 Mar 2022
Next filing: 18 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LJPC	Common Stock	Award	$1,212	+334	+2.9%	$3.63	11,673	31 Mar 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LJPC	Employee Stock Option (Right to Buy)	Award	$0	+334		$0.000000	334	31 Mar 2022	Common Stock	334	$4.27	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired on 3/31/2022 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2	The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years.